|Year : 2010 | Volume
| Issue : 4 | Page : 557-559
Capecitabine-related intracranial hypotension syndrome mimicking dural metastasis in a breast cancer patient: Case report and review of the literature
Rusen Cosar-Alas1, Aykan Alas2, Alaattin Ozen1, Bengu Denizli1, Mert Saynak1, Sernaz Uzunoglu3, Nurettin Aydogdu4, Hakan Karagol3, Cem Uzal1, Zafer Kocak1
1 Department of Radiation Oncology, Trakya University Medical Faculty, Edirne, Turkey
2 Private Edirne Radiology Center, Edirne, Turkey
3 Department of Medical Oncology, Trakya University Medical Faculty, Edirne, Turkey
4 Department of Physiology, Trakya University Medical Faculty, Edirne, Turkey
|Date of Web Publication||24-Feb-2011|
Trakya University, Faculty of Medicine, Department of Radiation Oncology, 22030 Edirne
Source of Support: None, Conflict of Interest: None
Spontaneous intracranial hypotension (SICH) is an entity, which is secondary to iatrogenic manipulation and breaching of dura. Postural headache in patients should be suspected, cranial magnetic resonance imaging (MRI) is essential for precise diagnosis. Hallmark of MRI is regular shape of pachymeningeal gadolinium enhancement and subdural effusion. It may mimic central nervous system (CNS) metastasis. Prevention of such cases from receiving cranial radiotherapy by misinterpretation of the gadolinium enhancement as CNS metastasis is an important issue. Capecitabine is an antineoplastic agent, of which metabolites can cross blood-brain barrier in CNS via epithelial tissue. It may cause decrease in CSF production. SICH might be the clinical reflection of this decrease in CSF production. Review of the English literature revealed limited data because of the very little experience with oncologic patients suffering from intracranial hypotension. We report a case of spontaneous intracranial hypotension during capecitabine treatment. Patient was completely well following drug discontinuation and supportive treatment.
Keywords: Capecitabine, mimicking dural metastasis, orthostatic headache, spontaneous intracranial hypotension syndrome
|How to cite this article:|
Cosar-Alas R, Alas A, Ozen A, Denizli B, Saynak M, Uzunoglu S, Aydogdu N, Karagol H, Uzal C, Kocak Z. Capecitabine-related intracranial hypotension syndrome mimicking dural metastasis in a breast cancer patient: Case report and review of the literature. J Can Res Ther 2010;6:557-9
|How to cite this URL:|
Cosar-Alas R, Alas A, Ozen A, Denizli B, Saynak M, Uzunoglu S, Aydogdu N, Karagol H, Uzal C, Kocak Z. Capecitabine-related intracranial hypotension syndrome mimicking dural metastasis in a breast cancer patient: Case report and review of the literature. J Can Res Ther [serial online] 2010 [cited 2022 Jan 18];6:557-9. Available from: https://www.cancerjournal.net/text.asp?2010/6/4/557/77070
| > Introduction|| |
Intracranial hypotension is known as spontaneous intracranial hypotension (SICH) or secondary to iatrogenic manipulation and breaching of dura, following a lumbar puncture or cranial/spinal surgery. , The common MRI findings for this entity are the pachymeningeal enhancement, positive venous distention sign, ballooning of the vein of Galen, cerebellar ectopia. Dural gadolinium enhancement is often interpreted as dural metastasis which is seen in only 5% of patients with cancer. Therefore, distinctive diagnosis with SICH is very important in this particular group of patients. ,
In the presented case, diffuse regular pachimeningeal contrast enhancement, which mimicked static metastasis was obtained on cranial MRI, which was carried out to clarify the headache complaint during oral capecitabine treatment for metastatic breast cancer. Highly regular shape of pachymeningeal enhancement was suspicious for possible ICH on consultation by an experienced radiologist; therefore, the management of the patient was arranged as bed rest and intravenous dexamethasone treatment. Review of the literature revealed limited data because of the very little experience with oncologic patients suffering from intracranial hypotension.
| > Case Report|| |
A fifty-eight-year old postmenopausal woman with breast cancer received 6 cycles of fluorouracil, adriamycin and cyclophosphamide chemotherapy and locoregional radiotherapy following a right modified radical mastectomy (invasive ductal carcinoma T3N3M0, estrogen and progesterone receptor (+)) in November 2003. While being followed under tamoxifen treatment, multiple bone metastases were developed on the second year. The treatment was rearranged as local RT, monthly zoledronic acid injection, and exemestane, and the patient was put on follow-up. On the 52 th month, docetaxel chemotherapy was launched due to liver metastasis. Abdominal CT evaluation after three cycles of chemotherapy showed progression of liver metastases. Her chemotherapy schedule was changed to oral capecitabine 2500 mg/m 2 daily.
The patient reported intensive headache, nausea, vomiting, ptosis of left eyelid and lacrimation prior to fourth cycle of chemotherapy. She had ongoing lightheadedness since the first day, and on the twelfth day, she reported balance troubles. No hand-and-foot syndrome, diarrhea, or mucositis were reported. Laboratory test values including CBC, electrolytes, and thyroid function tests were within normal limits. Cranial MRI showed cerebellar and cerebral extensive subdural effusion and diffuse regular pachymeningeal gadolinium fixation [[Figure 1]a, [Figure 2]a, [Figure 3]a]. With possible diagnosis of having pachymeningeal metastatic involvement or SICH, she was instructed to discontinue capecitabine, bed rest, fluid intake, and 16 mg dexamethasone treatment daily and the symptoms subsided over the next few days. A control cranial MRI was planned for fifteen days later. On her following visit, the patient had no complaints. Control cranial MRI revealed a decrease in regular opacification of dura, which definitely ruled out a metastatic involvement of the CNS [Figure 1]b, [Figure 2]b,[Figure 3]b]. Another control cranial MRI was carried out on her fortieth day visit which showed complete remission in both of subdural effusion and regular pachymeningeal gadolinium fixation [[Figure 1]c, [Figure 2]c, [Figure 3]c]. Oral capecitabine treatment was continued for another four cycles when her performance status improved.
|Figure 1: Cranial MR images showing extensive cerebellar and cerebral effusion in coronal T2 weighted scans at the time of diagnosis (a), after fifteen days follow-up (b), at forty days follow-up (c)|
Click here to view
|Figure 2: Cranial MR images showing diffuse pachymeningeal enhancement in axial sections of post contrast T1 weighted scans at the time of diagnosis (a), after fifteen days follow-up (b), at forty days follow-up (c)|
Click here to view
|Figure 3: Cranial MR images showing sagittal sections of pre contrast scan at the time of diagnosis (a), and diffuse pachymeningeal enhancement in post contrast scans; after fifteen days follow-up (b), at forty days follow-up (c)|
Click here to view
| > Discussion|| |
Intracranial hypotension syndrome gained popularity with the recent developments in the radiologic intervention modalities. Cranial MRI is essential for the exact diagnosis. The characteristic MRI finding is diffuse and continuous thickening of the dura in the supratentorial and infratentorial areas. Other cranial MRI findings include intracranial pachymeningeal thickening and post-contrast enhancement, subdural fluid collections and downward displacement or "sagging" of the brain.  Spinal MRI findings include collapse of the dural sac with a festooned appearance, intense epidural enhancement due to dilatation of the epidural venous plexus, and possible epidural fluid collections.  It is important for the radiologists to be familiar with this entity and to have an index of suspicion for the imaging findings associated with intracranial hypotension syndrome. This will aid in diagnosis and initiation of early treatment for this debilitating condition.
The doctrine states that intracranial blood volume and CSF volume are inversely correlated with each other within the cranium.  Accordingly, intracranial pressure caused by a decrease in CSF volume is balanced with an increase in blood volume, especially in the venous system of which capacity is high. This reflex mechanism protects fragile nerve tissue continuously against the bony structures, which surrounds it via a buffering system like blood or CSF. In cases with intracranial hypotension, volume increase observed in sinuses, over cortical venous structures and epidural plexuses supports this theory. However, in spontaneous cases, the first treatment is bed rest, fluid, and caffeine intake.
The pathogenesis of capecitabine-induced neurotoxicity is not well understood but it is most likely attributed to its metabolites, 5′-DFUR and fluorouracil. Both of these metabolites were shown to can cross the blood-brain barrier in a phase I study.  Capecitabine may cross the blood-brain barrier via the human concentrative nucleoside transporter in the form of 5′-DFUR, which was converted to fluorouracil due to the high concentration of thymidine phosphorylase in brain cells. 
The mechanism of drug action is that it mainly concentrates on epithelial tissue. The choroid plexus produces 80% of the CSF. The ependymal (epithelial) cells that line the ventricles of the brain fuse with the pia mater to form the choroid plexuses. Pia layer originates from two layers and each are composed of villi covered with single-layered cuboidal epithelium.  Decreased production of CSF is one of the causes of SICH etiology and this might be another route of SICH caused by oral capecitabine.
In prospective information of oral capecitabine, it is mentioned that 5% of side effects of the drug is headache. We hereby want to emphasize that patients who receive oral capecitabine medication should be checked for headache complaint, and evaluated with cranial MRI. Awareness of SICH by radiation oncologist, medical oncologist and radiologist in oncology patients is extremely important in order to prevent the patient from receiving unnecessary treatment by misinterpretation of diffuse and continuous dural gadolinium enhancement as central nervous system metastasis.
| > References|| |
|1.||Rando TA, Fishman RA. Spontaneous intracranial hypotension: Report of two cases and review of the literature. Neurology 1992;42:481-7. |
|2.||Pannullo SC, Reich JB, Krol G, Deck MD, Posner JB.none MRI changes in intracranial hypotension. Neurology 1993;43:919-26. |
|3.||Forghani R, Farb RI. Diagnosis and temporal evolution of signs of intracranial hypotension on MR of the brain. Neuroradiology 2008;50:1025-34. |
|4.||Schievink WI, Gordon OK, Tourje J. Connective tissue disorders with spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension: A prospective study. Neurosurgery 2004;54:65-70. |
|5.||Chiapparini L, Ciceri E, Nappini S, Castellani MR, Mea E, Bussone G, et al. Headache and intracranial hypotension: Neuroradiological findings. Neurol Sci 2004;25:138-41. |
|6.||Chiapparini L, Farina L, D'Incerti L, Erbetta A, Pareyson D, Carriero MR, noneet al. Spinal radiological findings in nine patients with spontaneous intracranial hypotension. Neuroradiology 2002;44:143-52. |
|7.||Mokri B, Parisi JE, Scheithauer BW, Piepgras DG, Miller GM. none Meningeal biopsy in intracranial hypotension: Meningeal enhancement on MRI. Neurology 1995;45:1801-7. |
|8.||Heier MS, Heintz R, Fosså SD. Passage of 5′-dFUrd and its metabolites 5-FU and 5-FUH2 to CSF in a clinical phase 1 study. Acta Neurol Scand 1986;74:240-4. |
|9.||Mata JF, García-Manteiga JM, Lostao MP, Fernández-Veledo S, Guillén-Gómez E, Larrayoz IM,none et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 2001;59:1542-8. |
|10.||Welch K. Secretion of cerebrospinal fluid by choroid plexus of the rabbit. Am J Physiol 1963;205:617-24. |
[Figure 1], [Figure 2], [Figure 3]
|This article has been cited by|
||A case of intracranial hypotension caused by docetaxel treatment for metastatic breast cancer
| ||Hiroshi Nakagomi,Kazushige Furuya,Yuko Nakayama,Kazunori Takahashi,Masahiro Maruyama,Atushi Takano,Hidemitu Sugai,Masao Hada,Yoshiaki Miyasaka,Akitoshi Saito |
| ||International Cancer Conference Journal. 2014; |
|[Pubmed] | [DOI]|
||Headaches in Brain Tumor Patients: Primary or Secondary?
| ||Sarah Nelson,Lynne P. Taylor |
| ||Headache: The Journal of Head and Face Pain. 2014; 54(4): 776 |
|[Pubmed] | [DOI]|